Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates.

Publication date: Jul 29, 2025

System serology offers a comprehensive approach to evaluate the humoral immune response by evaluating multiple parameters. In the present study, based on four groups of individuals with a different history of SARS-CoV-2 immunization, we analyzed the serum of 180 individuals based on six serological methods to better decipher their immunity. Through our analysis, against different SARS-CoV-2 antigens or variants, we report the importance of system serology to better decipher population immunity. Fc-dependent parameters are key factors underlying the variability of humoral immune response triggered by different schemes of SARS-CoV-2 immunization. With an evolving exposure to new variants, the acquisition of robust cross-reactive Fc-dependent effector functions are likely to be key to control viral replication when neutralizing antibodies are poorly cross-reactive. As booster vaccination remains a useful tool in periodically bolstering humoral immunity, particularly in vulnerable populations, studies should continue to evaluate the humoral immune response using system serology approach.

Open Access PDF

Concepts Keywords
Antibodies Based
History Cov
Humoral Decipher
Vaccination Evaluate
Viral Fc
Humoral
Immune
Immunity
Immunization
Individuals
Parameters
Sars
Serology
System
Variants

Semantics

Type Source Name
disease IDO humoral immune response
disease IDO history
drug DRUGBANK Tropicamide
pathway KEGG Viral replication
disease MESH AuRA
pathway REACTOME Immune System
disease MESH COVID 19 pandemic
disease MESH syndrome
drug DRUGBANK Esomeprazole
disease MESH infection
disease MESH influenza
disease IDO immune response
disease IDO protein
drug DRUGBANK Coenzyme M
disease MESH vaccine breakthrough infection
disease IDO blood
drug DRUGBANK Pidolic Acid
disease IDO assay
disease MESH clinical relevance
drug DRUGBANK Piroxicam
drug DRUGBANK Trestolone
drug DRUGBANK L-Asparagine
disease MESH asymptomatic infections
drug DRUGBANK Serine
disease MESH seroconversion
drug DRUGBANK Clostridium tetani toxoid antigen (formaldehyde inactivated)
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Streptomycin
drug DRUGBANK Water
drug DRUGBANK Chloride ion
drug DRUGBANK Sodium acetate
drug DRUGBANK Ethanolamine
disease MESH dissociation
drug DRUGBANK Tretamine
disease IDO algorithm
drug DRUGBANK Glycine
drug DRUGBANK Tromethamine
pathway REACTOME Digestion
drug DRUGBANK Formic Acid
drug DRUGBANK Flunarizine
disease MESH privacy
disease MESH bacterial diseases
disease IDO susceptibility
disease MESH Respiratory Syncytial Virus Infection
disease IDO cell
disease IDO host
disease MESH virus infection
disease MESH convalescence
drug DRUGBANK Carboxyamidotriazole
drug DRUGBANK Dimercaprol
pathway REACTOME Reproduction

Original Article

(Visited 4 times, 1 visits today)